Gilead, Inc., The World Health Organization has established a goal of eliminating viral hepatitis (hepatitis B and hepatitis C) by the year 2030.
In support of this target, Gilead’s Medical Affairs team has created the CHIME Program (Conquering Hepatitis via Micro-Elimination), offering research grant funding for up to 30 hepatitis C virus (HCV) projects which focus on breaking down national and international HCV elimination goals into micro-elimination projects among smaller and more defined populations.
Gilead will support projects with research grants of up to $350,000 each, with an emphasis on achieving geographic distribution across the globe. Successful proposals will demonstrate clear scientific objectives, defined timelines, a comprehensive operational plan and the potential to generate data that has relevance to the medical community and policy makers.
Gilead, Inc., The World Health Organization has established a goal of eliminating viral hepatitis (hepatitis B and hepatitis C) by the year 2030.
In support of this target, Gilead’s Medical Affairs team has created the CHIME Program (Conquering Hepatitis via Micro-Elimination), offering research grant funding for up to 30 hepatitis C virus (HCV) projects which focus on breaking down national and international HCV elimination goals into micro-elimination projects among smaller and more defined populations.
Gilead will support projects with research grants of up to $350,000 each, with an emphasis on achieving geographic distribution across the globe. Successful proposals will demonstrate clear scientific objectives, defined timelines, a comprehensive operational plan and the potential to generate data that has relevance to the medical community and policy makers.
CHIME Program